Dr. Sagar Parikh, John F. Greden Professor of Depression and Clinical Neuroscience, and Professor of Psychiatry at the University of Michigan, discusses topline results from Sage and Biogen’s Phase 3 CORAL Study evaluating zuranolone, a once-daily, two-week, investigational drug in development for the treatment of major depressive disorder (MDD).
In March 2015, Dr. Sagar Parikh was appointed as the John F. Greden Professor of Depression and Clinical Neuroscience, and Professor of Psychiatry, at the University of Michigan, where he was also designated Associate Director of the Michigan Comprehensive Depression Center. Dr. Parikh is also adjunct Professor of Psychiatry at the University of Toronto, where he was on staff full-time from 1994-2015.
Dr. Parikh is the author / editor of two books and over 150 peer-reviewed articles and book chapters, and co-author of CANMAT(link is external) treatment guidelines for depression and for bipolar disorder, the world’s most cited mood disorder guidelines. He holds research grants from multiple funding agencies, covering studies in clinical treatments in mood disorders, health services research, genetics, epidemiology, and educational research. He has conducted clinical trials looking at the combination of medication and psychotherapy for bipolar disorder and for depression, as well as pharmacotherapy trials in mood disorders.